Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Receivables (2016 - 2025)

Firefly Neuroscience has reported Receivables over the past 15 years, most recently at $194000.0 for Q4 2025.

  • Quarterly results put Receivables at $194000.0 for Q4 2025, down 19.83% from a year ago — trailing twelve months through Dec 2025 was $194000.0 (down 19.83% YoY), and the annual figure for FY2025 was $194000.0, down 19.83%.
  • Receivables for Q4 2025 was $194000.0 at Firefly Neuroscience, down from $379000.0 in the prior quarter.
  • Over the last five years, Receivables for AIFF hit a ceiling of $3.7 million in Q2 2022 and a floor of $100000.0 in Q1 2025.
  • Median Receivables over the past 5 years was $1.5 million (2021), compared with a mean of $1.4 million.
  • Biggest five-year swings in Receivables: skyrocketed 156.94% in 2021 and later crashed 90.73% in 2023.
  • Firefly Neuroscience's Receivables stood at $1.9 million in 2021, then fell by 2.13% to $1.8 million in 2022, then tumbled by 90.73% to $168000.0 in 2023, then surged by 44.05% to $242000.0 in 2024, then decreased by 19.83% to $194000.0 in 2025.
  • The last three reported values for Receivables were $194000.0 (Q4 2025), $379000.0 (Q3 2025), and $394000.0 (Q2 2025) per Business Quant data.